Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Eligibility Criteria

• * Have a newly diagnosed, biopsy-proven adenocarcinoma of the pancreas.
• * Tumor must be deemed resectable by the study team
• * Patient's acceptance to have a tumor biopsy.
• * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
• * Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures.
• * Women of childbearing potential (WOCBP) must have a negative serum pregnancy test.
• * For both Women and Men, must use acceptable form of birth control while on study.
• * Received any anti-pancreatic cancer therapy (symptomatic therapies are allowed), or any prior anti-cancer immunotherapy.
• * Diagnosed with another cancer whose natural history or treatment could interfere with safety or efficacy assessments on this study.
• * Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
• * Active autoimmune disease.
• * Systemic steroid therapy (\> 10mg daily prednisone equivalent) or immunosuppressive therapy within 14 days of first dose of study drug administration.
• * Active infection requiring systemic therapy.
• * Known history of human immunodeficiency virus (HIV).
• * Active or chronic hepatitis B or hepatitis C.
• * Known active tuberculosis.
• * History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases, chronic obstructive pulmonary disease (COPD), asthma requiring medication, etc.
• * Prior allogeneic stem cell transplantation or organ transplantation.
• * Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drug.
• * Received a live vaccine ≤ 28 days before first dose of study drug.
• * History of severe hypersensitivity reaction to any monoclonal antibody
• * Concurrent participation in another therapeutic clinical study
• * Pregnant or breastfeeding